TriSalus Life Sciences, Inc. (TLSI) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2021
Loading P/E history...
TLSI Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, TriSalus Life Sciences, Inc. (TLSI) trades at a price-to-earnings ratio of -2.4x, with a stock price of $4.46 and trailing twelve-month earnings per share of $-0.84.
The current P/E is 102% below its 5-year average of 120.2x. Over the past five years, TLSI's P/E has ranged from a low of 64.7x to a high of 175.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, TLSI trades at a 111% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, TLSI trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TLSI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TLSI P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $1B | 25.2 | 0.69 | -65% | |
| $115B | 16.3 | - | +178% | |
| $277B | 15.4 | 0.73 | +8% | |
| $74B | 17.1 | 2.70 | +8% | |
| $84B | 29.2 | - | +55% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TLSI Historical P/E Data (2021–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $9.88 | $0.15 | 64.7x | -46% |
| FY2021 Q3 | $9.93 | $0.06 | 175.8x | +46% |
Average P/E for displayed period: 120.2x
See TLSI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TLSI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TLSI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTLSI — Frequently Asked Questions
Quick answers to the most common questions about buying TLSI stock.
Is TLSI stock overvalued or undervalued?
TLSI trades at -2.4x P/E, below its 5-year average of 120.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does TLSI's valuation compare to peers?
TriSalus Life Sciences, Inc. P/E of -2.4x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is TLSI's PEG ratio?
TLSI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2021.